National Health Act 1953 - Amendment declaration under subsections 85(2) and 85(2AA) - Amendment determination under subsection 85(2A) - drugs and medicinal preparations (No. PB 4 of 2010)

Overview

The National Health Act 1953 was amended in 2010 through legislative instrument F2010L00471 to update the Pharmaceutical Benefits Scheme (PBS). The Act, enacted by the Australian Parliament, establishes the PBS to ensure Australians have access to affordable and effective medicines. The legislative instrument updates the list of drugs and medicinal preparations available under the PBS, reflecting recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). The PBAC, an independent body comprising experts from various fields, advises the Minister on which drugs and preparations should be included on the PBS, considering factors such as clinical effectiveness, safety, and cost-effectiveness. This amendment, which came into effect on 1 March 2010, includes the addition of new drugs like nebivolol and ustekinumab, the deletion of others such as the influenza vaccine, and modifications to the availability and prescribing conditions for various medications. The changes aim to align the PBS with current medical needs and advancements in pharmaceutical treatments.

Scope and Application

The National Health Act 1953, specifically amended by the legislation F2010L00471, applies to the Pharmaceutical Benefits Scheme (PBS) under Part VII, which ensures Australians have access to affordable medications. The Act applies to drugs and medicinal preparations declared by the Minister, which are then listed as pharmaceutical benefits. The legislation encompasses the declaration of new drugs, the revocation or variation of existing listings, and the determination of drug forms and administration methods. The amendments set out in the legislation involve changes to the list of drugs and the circumstances under which these pharmaceutical benefits can be prescribed. These amendments are implemented through Schedule 1, which details additions, deletions, and alterations to the list of drugs and the conditions for their use. The geographic reach of this legislation is national, as it pertains to the Commonwealth's role in providing pharmaceutical benefits across Australia. The amendments in the legislation are applicable to all entities and individuals involved in the prescription, supply, and administration of these pharmaceutical benefits. The Pharmaceutical Benefits Advisory Committee (PBAC) plays a crucial role in advising the Minister on the listing of drugs and their conditions, with any significant changes to drug listings requiring PBAC recommendations and parliamentary tabling. The instrument commenced on 1 March 2010, and the amendments include the addition of several new drugs, the deletion of others, and modifications to the circumstances of use for various medications.

Key Provisions

The National Health Act 1953 (the Act) is the foundational piece of legislation that governs the Pharmaceutical Benefits Scheme (PBS), through which the Commonwealth ensures all Australians have reliable, timely, and affordable access to a wide range of medicines (subsection 85(1)). The Act mandates that benefits are provided by the Commonwealth in accordance with Part VII, specifically in relation to pharmaceutical benefits. The Act requires the Minister to declare by legislative instrument which drugs and medicinal preparations are subject to Part VII (subsection 85(2)). These declared drugs and preparations are referred to as 'listed drugs' as defined in subsection 84(1). The Act also allows for the inclusion of certain extemporaneously-prepared medicinal preparations under Part VII through declarations under paragraph 85(2)(b). The Act imposes several obligations on the Minister, including determining the form and manner of administration of listed drugs through legislative instruments (subsections 85(3), 85(5), and 85(6)). These determinations govern what constitutes the pharmaceutical benefit under Part VII of the Act. The Act further empowers the Minister to revoke or vary declarations under subsection 85(2) by legislative instrument (subsection 85(2AA)). However, if a revocation or variation would result in a drug or medicinal preparation ceasing to be a listed drug, the Minister must obtain written advice from the Pharmaceutical Benefits Advisory Committee (PBAC) (subsection 85(2AB)). This advice must then be tabled in Parliament along with the relevant declaration (subsection 85(2AC)). Additionally, under subsection 101(4), a drug or medicinal preparation cannot be declared under paragraph 85(2)(a) unless the PBAC has recommended to the Minister that it be so declared. Under the Act, breaches of its provisions can result in both civil and criminal consequences. The Act does not explicitly outline specific offences or penalties for non-compliance with its provisions. However, general offences and penalties under the Act could include fines and imprisonment for wilful or negligent breaches. The exact penalties depend on the nature and severity of the breach, but they are generally aligned with the severity of the contravention. The Minister may also be required to take corrective actions, such as revoking or varying declarations, to ensure compliance with the Act.